Here are five key notes on the agreement:
1. The GELSYN-3 is a three-injection, hyaluronic acid product for pain relieve in osteoarthritis patients.
2. The system is indicated for use in patients with knee osteoarthritis and designed for patients to have a more active lifestyle and potentially delay total knee replacement.
3. Financial terms of the agreement weren’t disclosed.
4. Hyaluronic acid products are used to lubricate and cushion joints and relieve arthritis pain. Patients can use GELSYN-3 to relieve pain up to 26 weeks.
5. The product has FDA clearance, earned in 2014, and Bioventus plans to launch the GELSYN-3 on the U.S. market in the third quarter of this year.
More articles on orthopedic devices:
RTI Surgical launches anterior cervical fixation system: 5 key notes
26 spine devices receive FDA 510(k) clearance in January
Stryker, Titan Spine, ConforMIS & more: 16 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
